Oct 2026· Cellular and Molecular Gastroenterology and Hepatology· pp.
101917
· 0 citations
Medicine
TL;DR
This study uncovers a novel mechanism that CXCR4-enriched B cells in gastric tumor tissues suppress T cell immunity via adenosine-mediated IL-10 production, which may contribute to tumor immune escape and disease progression of GC.
Abstract
Background
&
Aims
B cells are one major component of immune cells infiltrated in human solid tumors. However, the role of tumor-infiltrating B cells in mediating disease progression of human gastric cancer (GC) remains elusive.
Methods
Flow cytometry, immunohistochemistry and immunofluorescence were performed to analyze the prevalence, phenotypic and functional features of B cells in different samples of GC patients. B cells and T cells were purified and cultured ex vivo for regulation and functional assays. Tumor responses to B cell deficiency or adoptively transferred IL10 knockout B cells or blockade of CXCR4 or CD73 were measured in an in vivo syngeneic male mouse model.
Results
GC patients showed a significantly increased B cell enrichment in the tumor tissues during disease progression. The accumulation of B cells in the tumor tissues was mediated by the CXCL12/CXCR4 chemotactic axis. Although a similar phenotypic feature of B cells was shown between tumor and non-tumor tissues, tumor-infiltrating B cells effectively suppressed T cell immunity and accelerated tumor growth via IL-10 ex vivo and in vivo. In addition, tumor-associated adenosine could promote the production of IL-10 by B cells, and inhibiting the rate limiting enzyme CD73 for adenosine production in vivo significantly suppressed IL-10 production of tumor-infiltrating B cells and attenuated GC growth.
Conclusions
Our study uncovers a novel mechanism that CXCR4-enriched B cells in gastric tumor tissues suppress T cell immunity via adenosine-mediated IL-10 production, which may contribute to tumor immune escape and disease progression of GC.
B cells can suppress anti-tumor T cell responses, representing a potential mechanism of resistance to immunotherapy. Multiple Breg subsets have been described in humans and mice. Bregs inhibit anti-tumor immunity through cytokine secretion, immune checkpoint expression, and potentially adenosine generation, which colle...
Hannah R. Hall, Jeffrey Song, N. Kren et al.· Frontiers in Immunology· 0 citations
Effector B cell responses in solid malignancies are associated favorable response to immunotherapy. B cells can amplify anti-tumor immune responses via antibody production, antigen presentation, and pro-inflammatory cytokine release; yet B cells in cancer patients and tumor-bearing mice often fail to support these fu...
Pancreatic ductal adenocarcinoma (PDAC) remains largely refractory to immunotherapy because of its immunosuppressive, T-cell–excluded microenvironment. Immune checkpoint blockade, alone or with chemotherapy, has shown limited efficacy, likely due to redundant suppressive pathways. CAF-derived CXCL12 acting throug...
I. Pellicciotta, G. Manji, A. Raufi et al.· Cancer Research· 0 citations
Findings reveal that cancer cell-derived anaphylatoxin C5a plays a pivotal role in promoting an inhibitory TIME in liver tumor tissues and blocking the C5a/C5ar1 axis in combination with immune checkpoint inhibitors could represent a promising strategy for treating HCC.
Run Huang, Tian-Hao Chu, Guiqi Zhu et al.· Cancer Letters· 0 citations
This review systematically summarizes the classification and identification of myeloid-derived suppressor cells, their biological properties in the context of tumors and autoimmune diseases, genetic and signaling pathway regulatory mechanisms, differentiation skewing in the TME, and cellular interactions with the TME.
Rong-Jun Deng, Xiu-Yun Bai, Jue Yang et al.· Signal Transduction and Targ...· 0 citations
The paradox of immune resistance in High-Grade Serous Carcinoma (HGSC) of the ovary, despite high immune cell infiltration, is caused by a complex, multi-layered immunosuppressive tumor microenvironment (TME) that disables and excludes effector immune cells. This is resolved by the aggressive co-option of immunosuppres...
C. Bose· Discover Immunity· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.